Molenzavir 200 Capsule: Each capsule contains Molnupiravir INN 200 mg.
Molnupiravir is an
investigational antiviral drug, which is the prodrug of the
ribonucleoside analog N4-hydroxycytidine. It inhibits the replication of
multiple RNA viruses, including
SARS-CoV-2. It has broad spectrum antiviral activity against influenza virus and coronaviruses, such as MERS-CoV, and SARS-CoV. It is aimed at the treatment of COVID-19 in-
• patients hospitalized due to mild, moderate or severe disease,
• non-hospitalized patients with mild or moderate disease.
Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Dosage & Administration
* 800 mg (4 capsules), Twice daily, 5 days, Orally
The safety & efficacy of Molnupiravir in patients below 18 years of age have not been established. No dosage adjustment is required for renal, hepatic impairment & elderly
Common adverse reactions are diarrhoea, nausea, dizziness, headache, rash and urticaria etc
Use in Pregnancy & Lactation
There are no data from the use of
Molnupiravir in pregnant women. Studies in animals have shown
reproductive toxicity. It is not recommended during pregnancy.
It is unknown whether Molnupiravir or any of the components of Molnupiravir is present in human milk, affects human milk production, or has effect on the breastfed infant.
No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with molnupiravir
Do not store above 30 ⁰C. Keep away from light and out of the reach of children.
Molenzavir 200: Each box contains 5 Alu-Alu blister strips of 4 capsules.